Precision Biosciences Stock Alpha and Beta Analysis
| DTIL Stock | USD 4.62 0.13 2.74% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Precision BioSciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Precision BioSciences over a specified time horizon. Remember, high Precision BioSciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Precision BioSciences' market risk premium analysis include:
Beta 2.06 | Alpha (0.34) | Risk 3.61 | Sharpe Ratio (0.07) | Expected Return (0.24) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Precision | Build AI portfolio with Precision Stock |
Precision BioSciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Precision BioSciences market risk premium is the additional return an investor will receive from holding Precision BioSciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Precision BioSciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Precision BioSciences' performance over market.| α | -0.34 | β | 2.06 |
Precision BioSciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Precision BioSciences' Buy-and-hold return. Our buy-and-hold chart shows how Precision BioSciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Precision BioSciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Precision BioSciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Precision BioSciences shares will generate the highest return on investment. By understating and applying Precision BioSciences stock market price indicators, traders can identify Precision BioSciences position entry and exit signals to maximize returns.
Precision BioSciences Return and Market Media
The median price of Precision BioSciences for the period between Mon, May 5, 2025 and Sun, Aug 3, 2025 is 4.88 with a coefficient of variation of 7.76. The daily time series for the period is distributed with a sample standard deviation of 0.38, arithmetic mean of 4.85, and mean deviation of 0.3. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Precision BioSciences Inc Reports Q1 2025 EPS of and Revenue Below 0. ... | 05/15/2025 |
2 | Disposition of 9826 shares by Brown Melinda of Precision BioSciences subject to Rule 16b-3 | 05/27/2025 |
3 | Acquisition by John Kelly of 82750 shares of Precision BioSciences subject to Rule 16b-3 | 06/02/2025 |
4 | Acquisition by Frankel Stanley of 21000 shares of Precision BioSciences subject to Rule 16b-3 | 06/06/2025 |
5 | Acquisition by Germano Geno J of 21000 shares of Precision BioSciences subject to Rule 16b-3 | 06/09/2025 |
6 | Precision BioSciences Gains on FDA Pediatric Disease Designation | 06/25/2025 |
7 | Disposition of 14827 shares by John Kelly of Precision BioSciences at 4.26 subject to Rule 16b-3 | 07/03/2025 |
8 | Precision BioSciences Reveals Promising Preclinical Data for Gene Editing Program DTIL ... | 07/16/2025 |
9 | Precision BioSciences Secures Orphan Drug Status for DMD Treatment DTIL Stock News | 07/17/2025 |
10 | Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of ... | 07/23/2025 |
11 | Should I hold or sell Precision BioSciences Inc. stock in 2025 - Stock Market Recommendation With Low Risk - jammulinksnews.com | 08/01/2025 |
About Precision BioSciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Precision or other stocks. Alpha measures the amount that position in Precision BioSciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2024 | 2025 (projected) | Payables Turnover | 13.79 | 3.2 | 3.04 | Days Of Inventory On Hand | 306.14 | 275.53 | 244.91 |
Precision BioSciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Precision BioSciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Precision BioSciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Precision BioSciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Precision BioSciences. Please utilize our Beneish M Score to check the likelihood of Precision BioSciences' management manipulating its earnings.
| 14th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 14th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Precision BioSciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Precision BioSciences Backtesting, Precision BioSciences Valuation, Precision BioSciences Correlation, Precision BioSciences Hype Analysis, Precision BioSciences Volatility, Precision BioSciences History and analyze Precision BioSciences Performance. For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Precision BioSciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.